Selected research
Market Structure
Global Angiopoietin 2 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Angiopoietin 2 market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Angiopoietin 2 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Angiopoietin 2 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Angiopoietin 2 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Angiopoietin 2 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Angiopoietin 2 include Eli Lilly and Company, Amgen Inc., Synergys Biotherapeutics, Inc., Silence Therapeutics Plc, RXi Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc., MedImmune, LLC, F. Hoffmann-La Roche Ltd. and Boehringer Ingelheim GmbH, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Angiopoietin 2 market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Angiopoietin 2 and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Angiopoietin 2 sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Angiopoietin 2 market size, projected growth trends, production technologies, key applications, and end-use industries.
Angiopoietin 2 Segment by Company
Eli Lilly and Company
Amgen Inc.
Synergys Biotherapeutics, Inc.
Silence Therapeutics Plc
RXi Pharmaceuticals Corporation
Regeneron Pharmaceuticals, Inc.
MedImmune, LLC
F. Hoffmann-La Roche Ltd.
Boehringer Ingelheim GmbH
AnGes MG, Inc.
Angiopoietin 2 Segment by Type
Atu-111
BI-836880
LY-3127804
MEDI-3617
Others
Angiopoietin 2 Segment by Application
Hospital
Clinic
Others
Angiopoietin 2 Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Angiopoietin 2 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Angiopoietin 2 and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Angiopoietin 2.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Angiopoietin 2 market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Angiopoietin 2 manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Angiopoietin 2 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Angiopoietin 2 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Atu-111
- BI-836880
- LY-3127804
- MEDI-3617
- Others
Applications
- Hospital
- Clinic
- Others
Companies covered
- Eli Lilly and Company
- Amgen Inc.
- Synergys Biotherapeutics, Inc.
- Silence Therapeutics Plc
- RXi Pharmaceuticals Corporation
- Regeneron Pharmaceuticals, Inc.
- MedImmune, LLC
- F. Hoffmann-La Roche Ltd.
- Boehringer Ingelheim GmbH
- AnGes MG, Inc.
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Angiopoietin 2 Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Angiopoietin 2 Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Angiopoietin 2 Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Angiopoietin 2 Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Angiopoietin 2 Market Dynamics
- 2.1 Angiopoietin 2 Industry Trends
- 2.2 Angiopoietin 2 Industry Drivers
- 2.3 Angiopoietin 2 Industry Opportunities and Challenges
- 2.4 Angiopoietin 2 Industry Restraints
3 Angiopoietin 2 Market by Manufacturers
- 3.1 Global Angiopoietin 2 Revenue by Manufacturers (2021-2026)
- 3.2 Global Angiopoietin 2 Sales by Manufacturers (2021-2026)
- 3.3 Global Angiopoietin 2 Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Angiopoietin 2 Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Angiopoietin 2 Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Angiopoietin 2 Manufacturers, Product Type & Application
- 3.7 Global Angiopoietin 2 Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Angiopoietin 2 Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Angiopoietin 2 Players Market Share by Revenue in 2025
- 3.8.3 2025 Angiopoietin 2 Tier 1, Tier 2, and Tier 3
4 Angiopoietin 2 Market by Type
- 4.1 Angiopoietin 2 Type Introduction
- 4.1.1 Atu-111
- 4.1.2 BI-836880
- 4.1.3 LY-3127804
- 4.1.4 MEDI-3617
- 4.1.5 Others
- 4.2 Global Angiopoietin 2 Sales by Type
- 4.2.1 Global Angiopoietin 2 Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Angiopoietin 2 Sales by Type (2021-2032)
- 4.2.3 Global Angiopoietin 2 Sales Market Share by Type (2021-2032)
- 4.3 Global Angiopoietin 2 Revenue by Type
- 4.3.1 Global Angiopoietin 2 Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Angiopoietin 2 Revenue by Type (2021-2032)
- 4.3.3 Global Angiopoietin 2 Revenue Market Share by Type (2021-2032)
5 Angiopoietin 2 Market by Application
- 5.1 Angiopoietin 2 Application Introduction
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.1.3 Others
- 5.2 Global Angiopoietin 2 Sales by Application
- 5.2.1 Global Angiopoietin 2 Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Angiopoietin 2 Sales by Application (2021-2032)
- 5.2.3 Global Angiopoietin 2 Sales Market Share by Application (2021-2032)
- 5.3 Global Angiopoietin 2 Revenue by Application
- 5.3.1 Global Angiopoietin 2 Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Angiopoietin 2 Revenue by Application (2021-2032)
- 5.3.3 Global Angiopoietin 2 Revenue Market Share by Application (2021-2032)
6 Global Angiopoietin 2 Sales by Region
- 6.1 Global Angiopoietin 2 Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Angiopoietin 2 Sales by Region (2021-2032)
- 6.2.1 Global Angiopoietin 2 Sales by Region (2021-2026)
- 6.2.2 Global Angiopoietin 2 Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Angiopoietin 2 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Angiopoietin 2 Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Angiopoietin 2 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Angiopoietin 2 Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Angiopoietin 2 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Angiopoietin 2 Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Angiopoietin 2 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Angiopoietin 2 Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Angiopoietin 2 Revenue by Region
- 7.1 Global Angiopoietin 2 Revenue by Region
- 7.1.1 Global Angiopoietin 2 Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Angiopoietin 2 Revenue by Region (2021-2026)
- 7.1.3 Global Angiopoietin 2 Revenue by Region (2027-2032)
- 7.1.4 Global Angiopoietin 2 Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Angiopoietin 2 Revenue (2021-2032)
- 7.2.2 North America Angiopoietin 2 Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Angiopoietin 2 Revenue (2021-2032)
- 7.3.2 Europe Angiopoietin 2 Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Angiopoietin 2 Revenue (2021-2032)
- 7.4.2 Asia-Pacific Angiopoietin 2 Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Angiopoietin 2 Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Angiopoietin 2 Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Eli Lilly and Company
- 8.1.1 Eli Lilly and Company Company Information
- 8.1.2 Eli Lilly and Company Business Overview
- 8.1.3 Eli Lilly and Company Angiopoietin 2 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Eli Lilly and Company Angiopoietin 2 Product Portfolio
- 8.1.5 Eli Lilly and Company Recent Developments
- 8.2 Amgen Inc.
- 8.2.1 Amgen Inc. Company Information
- 8.2.2 Amgen Inc. Business Overview
- 8.2.3 Amgen Inc. Angiopoietin 2 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Amgen Inc. Angiopoietin 2 Product Portfolio
- 8.2.5 Amgen Inc. Recent Developments
- 8.3 Synergys Biotherapeutics, Inc.
- 8.3.1 Synergys Biotherapeutics, Inc. Company Information
- 8.3.2 Synergys Biotherapeutics, Inc. Business Overview
- 8.3.3 Synergys Biotherapeutics, Inc. Angiopoietin 2 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Synergys Biotherapeutics, Inc. Angiopoietin 2 Product Portfolio
- 8.3.5 Synergys Biotherapeutics, Inc. Recent Developments
- 8.4 Silence Therapeutics Plc
- 8.4.1 Silence Therapeutics Plc Company Information
- 8.4.2 Silence Therapeutics Plc Business Overview
- 8.4.3 Silence Therapeutics Plc Angiopoietin 2 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Silence Therapeutics Plc Angiopoietin 2 Product Portfolio
- 8.4.5 Silence Therapeutics Plc Recent Developments
- 8.5 RXi Pharmaceuticals Corporation
- 8.5.1 RXi Pharmaceuticals Corporation Company Information
- 8.5.2 RXi Pharmaceuticals Corporation Business Overview
- 8.5.3 RXi Pharmaceuticals Corporation Angiopoietin 2 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 RXi Pharmaceuticals Corporation Angiopoietin 2 Product Portfolio
- 8.5.5 RXi Pharmaceuticals Corporation Recent Developments
- 8.6 Regeneron Pharmaceuticals, Inc.
- 8.6.1 Regeneron Pharmaceuticals, Inc. Company Information
- 8.6.2 Regeneron Pharmaceuticals, Inc. Business Overview
- 8.6.3 Regeneron Pharmaceuticals, Inc. Angiopoietin 2 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Regeneron Pharmaceuticals, Inc. Angiopoietin 2 Product Portfolio
- 8.6.5 Regeneron Pharmaceuticals, Inc. Recent Developments
- 8.7 MedImmune, LLC
- 8.7.1 MedImmune, LLC Company Information
- 8.7.2 MedImmune, LLC Business Overview
- 8.7.3 MedImmune, LLC Angiopoietin 2 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 MedImmune, LLC Angiopoietin 2 Product Portfolio
- 8.7.5 MedImmune, LLC Recent Developments
- 8.8 F. Hoffmann-La Roche Ltd.
- 8.8.1 F. Hoffmann-La Roche Ltd. Company Information
- 8.8.2 F. Hoffmann-La Roche Ltd. Business Overview
- 8.8.3 F. Hoffmann-La Roche Ltd. Angiopoietin 2 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 F. Hoffmann-La Roche Ltd. Angiopoietin 2 Product Portfolio
- 8.8.5 F. Hoffmann-La Roche Ltd. Recent Developments
- 8.9 Boehringer Ingelheim GmbH
- 8.9.1 Boehringer Ingelheim GmbH Company Information
- 8.9.2 Boehringer Ingelheim GmbH Business Overview
- 8.9.3 Boehringer Ingelheim GmbH Angiopoietin 2 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Boehringer Ingelheim GmbH Angiopoietin 2 Product Portfolio
- 8.9.5 Boehringer Ingelheim GmbH Recent Developments
- 8.10 AnGes MG, Inc.
- 8.10.1 AnGes MG, Inc. Company Information
- 8.10.2 AnGes MG, Inc. Business Overview
- 8.10.3 AnGes MG, Inc. Angiopoietin 2 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 AnGes MG, Inc. Angiopoietin 2 Product Portfolio
- 8.10.5 AnGes MG, Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Angiopoietin 2 Value Chain Analysis
- 9.1.1 Angiopoietin 2 Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Angiopoietin 2 Production Mode & Process
- 9.2 Angiopoietin 2 Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Angiopoietin 2 Distributors
- 9.2.3 Angiopoietin 2 Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst